AUPH · XBRL financial data

Aurinia Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AUPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	50,118	45,605	134,030	175,513	235,133	283,055
Cost of revenue	0	1,091	5,664	14,148	28,248	32,665
Research and development	50,327	51,139	44,988	49,641	20,785	32,505
Selling, general and administrative	97,300	171,400	196,400	195,000	—	—
General and administrative	95,983	171,438	196,371	195,036	172,028	101,794
Total operating expenses	154,408	—	—	267,204	239,820	178,141
Other operating income (expense)	6,809	(574)	1,523	(8,379)	4,347	(9,530)
Operating income (loss)	(104,290)	(180,735)	(111,470)	(91,691)	(4,687)	104,914
Interest income	—	—	5,118	16,997	16,970	13,573
Interest expense	—	0	0	2,775	4,835	4,330
Income tax expense (benefit)	(94)	760	1,828	551	1,696	(173,045)
Net income (loss)	(102,680)	(180,966)	(108,180)	(78,020)	5,752	287,202
Earnings per share, basic USD per share	(0.87)	(1.40)	(0.76)	(0.54)	0.04	2.14
Earnings per share, diluted USD per share	(0.87)	(1.40)	(0.76)	(0.54)	0.04	2.07
Weighted average shares, basic thousands of shares	118,473	129,369	141,915	143,236	143,057	134,367
Weighted average shares, diluted thousands of shares	118,473	129,369	141,915	143,236	146,194	138,700

Fiscal years (AUPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	272,350	231,643	94,088	48,755	83,396	80,160
Marketable securities	125,979	234,178	295,218	301,614	275,043	317,784
Inventory	13,927	19,326	24,752	39,705	39,228	45,690
Prepaid and other current assets	7,171	12,506	—	—	—	—
Total current assets	419,427	513,324	442,539	424,800	446,596	491,967
Property and equipment, net	4,786	4,418	3,650	3,354	2,731	2,111
Right-of-use asset	5,489	5,383	4,907	4,498	4,068	3,596
Total assets	463,661	543,367	470,860	548,062	550,645	751,587
Accounts payable	—	—	—	4,327	5,187	3,313
Accrued liabilities	—	—	—	50,062	64,971	66,621
Total current liabilities	31,997	40,646	46,107	77,188	97,763	93,724
Lease liability, non-current	7,619	7,680	7,152	6,530	5,743	4,900
Total liabilities	55,911	64,276	65,425	170,108	173,167	170,256
Accumulated deficit	(575,156)	(756,122)	(864,302)	(942,322)	(936,570)	(649,368)
Total stockholders' equity	407,750	479,091	405,435	377,954	377,478	581,331
Total liabilities and equity	463,661	543,367	470,860	548,062	550,645	751,587
Common shares outstanding (cover page) thousands of shares	127,451	141,654	142,577	144,618	137,339	132,971

Fiscal years (AUPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(102,680)	(180,966)	(108,180)	(78,020)	5,752	287,202
Stock-based compensation	17,454	31,243	32,300	45,311	31,596	14,678
Depreciation and amortization	1,371	2,761	2,706	11,647	19,445	19,449
Net cash from operating activities	(69,858)	(157,692)	(79,529)	(33,461)	44,388	135,658
Net cash from investing activities	(158,186)	(103,870)	(60,632)	(6,706)	39,262	(32,768)
Proceeds from issuing common stock	187,732	196,740	0	0	1,084	756
Proceeds from issuing equity	573,143	—	—	—	—	—
Share repurchases	—	—	0	0	40,239	98,156
Net cash from financing activities	194,375	221,112	2,433	(5,130)	(49,092)	(106,110)
Net change in cash	(33,669)	(40,450)	(137,728)	(45,297)	34,558	(3,220)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aurinia Pharmaceuticals	45,792	83,699	46,367*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Harrow	83,889	70,661	(9,755)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Novavax	191,458	56,698	(72,807)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Neogen	172,000	222,800	12,900	218.3M	—	Q1 FY27 10-QAug 31, 2026
Akebia Therapeutics	155,548	49,128	3,525*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	172,860	25,752	(92,773)*	113.6M	9.0 quarters	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129,467	199,878	71,323*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	79,813	77,467	22,205*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Ardelyx	46,317	127,655	2,171*	251.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.